ALDX vs ODTX
ALDX: Aldeyra is a clinical-stage biotech pursuing FDA approval of reproxalap, an aldehyde dehydrogenase activator for ophthalmologic inflammation, dependent on addressing regulatory feedback and securing capital for development and commercialization. ODTX: A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
Side-by-side fundamentals
| Metric | ALDX | ODTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.70 | $18.61 | |
| Market cap as of 2026-07-23 | $106M | $865M | |
| Net margin as of 2026-07-23 | n/a | -3822.7% | |
| Operating margin as of 2026-07-23 | n/a | -4010.4% | |
| ROE as of 2026-07-23 | -57.3% | -69.0% | ALDX higher |
| ROA as of 2026-07-23 | -36.3% | -55.1% | ALDX higher |
| Debt / equity as of 2026-07-23 | 0.36 | 0.00 | ODTX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -19.0% | |
| Beta as of 2026-07-23 | 1.20 | 0.32 | |
| 1-year return as of 2026-07-22 close | -67.5% | +11.0% | ODTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.